Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds

Bioorg Med Chem Lett. 2022 Aug 1:69:128768. doi: 10.1016/j.bmcl.2022.128768. Epub 2022 May 2.

Abstract

Two betulinic acid derivatives, RPR103611 (2) and IC9564 (3) were previously reported to be potent HIV-1 entry inhibitors. In this current study, a SAR study of the triterpenoid moiety of 2 and 3 has been performed and an oleanolic acid derivative (4) was identified as a novel HIV-1 entry inhibitor. In addition, the combination of 4 with several-type of HIV-1 neutralizing antibodies provided significant synergistic effects. The synthetic utility of the CC double bond in the C-ring of 4 was also demonstrated to develop the 12-keto-type oleanolic acid derivative (5) as a potent anti-HIV compound. This simple transformation led to a significantly increased anti-HIV activity and a reduced cytotoxicity of the compound.

Keywords: Anti-HIV-1 activity; HIV-1 entry inhibitor; Neutralizing antibodies; SAR study; Triterpenoid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents*
  • HIV Fusion Inhibitors* / pharmacology
  • HIV-1*
  • Oleanolic Acid* / pharmacology
  • Triterpenes* / chemistry

Substances

  • Anti-HIV Agents
  • HIV Fusion Inhibitors
  • Triterpenes
  • Oleanolic Acid